论文部分内容阅读
目的:观察唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松症的临床疗效。方法:将120例糖尿病性骨质疏松患者随机分为实验组和对照组,实验组60例予唑来膦酸联合钙尔奇D治疗,对照组60例予钙尔奇D治疗。连续治疗12个月后,比较两组患者的骨密度、疼痛评分及不良反应的发生情况。结果:治疗12个月后,实验组患者的股骨颈、股骨粗隆和腰椎正位的骨密度均较对照组明显升高,差异有统计学意义(P<0.05);VAS疼痛评分较对照组显著降低(P<0.05)。治疗过程中,两组均无严重的不良反应发生。结论:唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松临床效果优于钙尔奇D单药治疗。
Objective: To observe the clinical efficacy of zoledronic acid plus calcium chloride in the treatment of diabetic osteoporosis. Methods: 120 cases of diabetic osteoporosis were randomly divided into experimental group and control group. 60 cases in the experimental group were treated with zoledronic acid plus calcium chloride D, and 60 cases in control group were treated with calcium chloride odd. After 12 months of continuous treatment, bone mineral density, pain scores and adverse reactions were compared between the two groups. Results: At 12 months after treatment, the BMD of the femoral neck, trochanter and lumbar vertebrae in the experimental group were significantly higher than those in the control group (P <0.05). VAS pain score was significantly higher than that in the control group Significantly lower (P <0.05). During the treatment, no serious adverse reactions occurred in both groups. CONCLUSION: Zoledronic acid combined with Calcium D in the treatment of diabetic osteoporosis is superior to the single dose of Calcium D monotherapy.